Propranolol and ICI-118,551 (ADRB2 antagonists) have shown to reduce the oxidative stress, stabilize the inflammatory response, and diminish the glycolytic pathway in ccRCC cells from VHL patients as well in a cell line. Here, ADRB2 is linked to nonpapillary renal cell carcinoma.